Premium
Immunological Evaluation of Co‐Assembling a Lipidated Peptide Antigen and Lipophilic Adjuvants: Self‐Adjuvanting Anti‐Breast‐Cancer Vaccine Candidates
Author(s) -
Aiga Taku,
Manabe Yoshiyuki,
Ito Keita,
Chang TsungChe,
Kabayama Kazuya,
Ohshima Shino,
Kametani Yoshie,
Miura Ayane,
Furukawa Hiroto,
Inaba Hiroshi,
Matsuura Kazunori,
Fukase Koichi
Publication year - 2020
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.202007999
Subject(s) - adjuvant , antigen , immune system , peptide , vaccination , cancer vaccine , vaccine adjuvant , immunology , chemistry , medicine , immunotherapy , biochemistry
Abstract Co‐assembling vaccines composed of a lipidated HER2‐derived antigenic CH401 peptide and either a lipophilic adjuvant, Pam 3 CSK 4 , α‐GalCer, or lipid A 506, were evaluated as breast cancer vaccine candidates. This vaccine design was aimed to inherit both antigen multivalency and antigen‐specific immunostimulation properties, observed in reported self‐adjuvanting vaccine candidates, by using self‐assembly and adjuvant‐conjugated antigens. Under vaccination concentrations, respective lipophilic adjuvants underwent co‐assembly with lipidated CH401, which boosted the anti‐CH401 IgG and IgM production. In particular, α‐GalCer was responsible for the most significant immune activation. Therefore, the newly developed vaccine design enabled the optimization of adjuvants against the antigenic CH401 peptide in a simple preparatory manner. Overall, the co‐assembling vaccine design opens the door for efficient and practical self‐adjuvanting vaccine development.